Casdin Capital’s Intellia Therapeutics NTLA Stock Holding History

Casdin Capital’s Portfolio NTLA Stock Details NTLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$4.55M	Buy	+355,000	New	+$4.52M	0.34%	28
2025 Q2	–	Sell	-2,000,000	Closed	-$14.2M	–	39
2025 Q1	$14.2M	Hold	2,000,000	–	–	1.16%	16
2024 Q4	$23.3M	Hold	2,000,000	–	–	1.55%	15
2024 Q3	$41.1M	Hold	2,000,000	–	–	2.74%	11
2024 Q2	$44.8M	Buy	2,000,000 +125,000	+7%	+$2.98M	3.42%	9
2024 Q1	$51.6M	Buy	1,875,000 +425,000	+29%	+$11.8M	3.83%	8
2023 Q4	$44.2M	Buy	1,450,000 +271,925	+23%	+$7.82M	4.34%	6
2023 Q3	$37.3M	Sell	1,178,075 -96,925	-8%	-$3.76M	4.12%	8
2023 Q2	$52M	Hold	1,275,000	–	–	4.54%	6
2023 Q1	$47.5M	Buy	1,275,000 +980,000	+332%	+$38.4M	3.91%	7
2022 Q4	$10.3M	Hold	295,000	–	–	0.8%	30
2022 Q3	$16.5M	Buy	+295,000	New	+$18.3M	1.08%	19

Other funds holding NTLA

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Regeneron Pharmaceuticals Tarrytown, New York $47.9M AUM 29.29% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Casdin Capital's NTLA Position: Q1 2026 in Review

Casdin Capital opened a new position in Intellia Therapeutics (NTLA) in Q1 2026: 355,000 shares worth $4.55M. The stake represents 0.34% of the portfolio and ranks #28 among its holdings. This is a return to the name: Casdin Capital previously reported a position in NTLA as recently as Q1 2025.

Casdin Capital first reported a position in NTLA in Q3 2022 and has held it in 12 quarters since. The position peaked at $52M in Q2 2023. 303 funds tracked by Wall St. Rank hold NTLA as of Q1 2026.

Casdin Capital held 355,000 shares of Intellia Therapeutics worth $4.55M as of Q1 2026.
Intellia Therapeutics was a new Casdin Capital position in Q1 2026.
Intellia Therapeutics made up 0.34% of Casdin Capital's portfolio in Q1 2026, its #28 holding.
Casdin Capital first reported a position in Intellia Therapeutics in Q3 2022 and has held it in 12 quarters since.
Casdin Capital's Intellia Therapeutics position peaked at $52M in Q2 2023.
303 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q1 2026.

Based on Casdin Capital's 13F filing for Q1 2026, filed 15 May 2026.